SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
Sara I. Pai(Yale University), Norah J. Shire(AstraZeneca (United States)), Sophie Wildsmith(AstraZeneca (United Kingdom)), Nawar Shara(MedStar Health), Carlo Resteghini(Humanitas University), Loren Lipworth(Vanderbilt University), Neus Basté(Hospital Clínic de Barcelona), Daniel Clayburgh(Oregon Health & Science University), Holger Mehlhorn(Klinik und Poliklinik für Hals-Nasen-Ohren-Heilkunde), Michael E. Stokes(Ithaka Harbors), George Fountzilas(Hellenic Cooperative Oncology Group), Philip Twumasi‐Ankrah(AstraZeneca (United States)), Edward S. Kim(The University of Texas MD Anderson Cancer Center), Jun Zhang(OSF HealthCare), Takashi Fujii(Saitama Cancer Center), Huifen Wang, Asud Khaliq(AstraZeneca (United States)), Giovanni Melillo(AstraZeneca (Brazil)), Derrick Lin(Massachusetts Eye and Ear Infirmary), Ezra E.W. Cohen(Moores Cancer Center)
Cited by 11
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
|The Lancet|2008|1.2k
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
|Immunity|2018|937